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INTRODUCTION
Endothelin has been identified as a neurohormone that is
activated during heart failure, and also by renin-angiotensin-
aldosterone, epinephrine-norepinephrine, and natriuretic pep-
tide. In addition, a number of studies have shown that endo-
thelin-1 and its receptors over ischemic myocardial tissue are
increased during ischemia-reperfusion injury. The endothe-
lin-1 is the principal isoform in disease states and also is the
most potent vasoconstrictor. It induces myocardial injury
during ischemia and reperfusion as a contributor (1).
There are numerous reports about the relationship between
endothelin and congestive heart failures (CHF). Some authors
showed that endothelin-1 is an independent, noninvasive pre-
dictor of functional and hemodynamic response to therapy
in patients with CHF. The majority of heart failure is caused
by cardiomyopathy, and the increased endothelin levels have
also been observed in the cardiomyopathy heart such as car-
diomyopathic Syrian hamsters (2) or in the experimental Cha-
gas’ cardiomyopathic hearts infected with Trypanosoma cruzi (3).
Tezosentan, the first intravenous endothelin A and B recep-
tor antagonist, has been evaluated as the treatment for acute
and chronic heart failure. There are two large randomized con-
trolled studies about tezosentan on acute heart failure syn-
drome-RITZ (randomized intravenous tezosentan study) and
VERITAS (value of endothelin receptor inhibition with tezo-
sentan in acute heart failure studies) (4, 5). Although these
studies demonstrated mixed results of tezosentan as the drug
of treatment for decompensated heart failure, the roles of the
myocardial protective effect of tezosentan in various heart fail-
ure models have not yet been defined. The objectives of this
experiment are to evaluate the myocardial protective effects
of tezosentan in various experimental heart failure models.
MATERIALS AND METHODS
Animals
Total 90 Sprague-Dawley male rats (6-8 weeks old, 200-
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Myocardial Protective Effect of Tezosentan, an Endothelin Receptor
Antagonist, for Ischemia-Reperfusion Injury in Experimental Heart 
Failure Models
The myocardial protective effects of endothelin antagonist in ischemic cardiomyopa-
thy (ICMP), doxorubicin-induced cardiomyopathy (DOX) and pressure-overload
hypertrophy by transverse aortic constriction (TAC) models have been predicted
to be different. The objective of this experiment, therefore, is to evaluate the myocar-
dial protective effect of tezosentan, an endothelin receptor antagonist, in various
experimental heart failure models. Sprague-Dawley rats (6-8 weeks old, 200-300
g) were randomized to three experimental groups (n=30 each): ICMP; DOX; and
TAC group. Each of these groups was randomly assigned further to the following
subgroups (n=10 each): sham-operated ischemia-reperfusion subgroup (SHAM);
tezosentan treated ischemia-reperfusion subgroup (Tezo); and tezosentan non-treat-
ed ischemia-reperfusion subgroup (N-Tezo). Total circulatory arrest was induced
for 1 hr, followed by 2 hr of reperfusion. The left ventricular developed pressure, peak
positive and negative first derivatives, and coronary blood flow were significantly dif-
ferent (P<0.05) among the SHAM, Tezo, and N-Tezo subgroups of the ICMP group
at 30 min of reperfusion, but there were no statistically significant differences among
the subgroups of the DOX and TAC groups. In conclusion, tezosentan, an endothe-
lin receptor antagonist, showed myocardial protection effects only on the ischemic
cardiomyopathy rat model, but not in the non-ischemic heart failure rat models.
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300 g) were housed at 20±2℃ and 55±20% humidity
with 12-hr light/dark cycles, and free access to food and water
in the Animal Care Facility at the Ansan Hospital, Korea Uni-
versity, Korea. This study was approved by the Committee
of Animal care of Korea University and conforms with the
Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996). 
Ischemic cardiomyopathy model (ICMP)
Rats were anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg), intraperitoneally. The endotracheal intu-
bation was performed, and positive pressure ventilation was
given using a mechanical ventilator (Harvard Apparatus,
South Natick, MA, U.S.A.) with room air at a respiratory
rate of 55-65 strokes/min and tidal volume of 10 mL/kg body
weight to maintain normal PO2, PCO2 and pH of blood.
Under the right lateral decubitus position, the left anterior
descending coronary artery was ligated with a 6-0 silk suture
through left anterior thoracotomy. The lungs were then inflat-
ed and the chest incision was closed. After recovery of self
respiration, extubation was performed. 
Doxorubicin-induced cardiomyopathy model (DOX)
Doxorubicin hydrochloride (D1515, Sigma Chemical Co,
St. Louis, MO, U.S.A.) was administrated in 6 equal injec-
tions (each intraperitoneal injection containing 2.5 mg/kg
in saline, for a total dose of 15 mg/kg) during 2 weeks. Rats
were observed for their general appearance, behavior, and mor-
tality for 4 weeks after the final injection.
Pressure-overload hypertrophy model by transverse 
aortic constriction (TAC)
Under sterile condition, the midline cervical incision was
performed; 1-2 cm incision was made at the level of cricoid
process and dissection down to the clavicle. After cutting of
the right clavicle, the thymus was retracted gently, and the
aortic arch was exposed. A constriction of the aortic arch was
conducted between the both carotid arteries using a 16 gauze
angiocatheter (internal diameter 0.6 mm).
Experimental design
We divided the experimental animals into three cardiomyo-
pathy groups; ischemic dilated cardiomyopathy group (ICMP,
n=30), doxorubicin-induced cardiomyopathy group (DOX,
n=30) and pressure-overload hypertrophy group by transverse
aortic constriction method (TAC, n=30). One month after the
construction of experimental rat groups, each group was fur-
ther randomly subdivided to a sham-operated ischemia-reper-
fusion subgroup (SHAM) operation (SHAM, n=10), tezosen-
tan treatment ischemia-reperfusion subgroup (Tezo, n=10),
or tezosentan non-treatment ischemia-reperfusion subgroup
(N-Tezo, n=10) (Fig. 1A). In the SHAM subgroup, only open
and closure procedures or injection of saline instead of dox-
orubicin were performed.
Ischemia-reperfusion protocols
Four weeks after the construction of cardiomyopathy mod-
els, the rats were anesthetized with sodium pentobarbital (50
mg/kg, intraperitoneally). Hearts were rapidly excised, con-
nected via the aorta to Langendorff apparatus (size 3, type
830, Hugo Sachs Elektronik, March-Hugstetten, Germany)
Sprague-Dawley
(200-300 gm, n=90) Reperfusion Total Circulatory
Arrest
Langendorff
perfusion
30 min 150 min 90 min 210 min
Ischemic
Dilated CMP
(ICMP, n=30)
Sham-operation
(Control group, n=10)
Saline-injection
(Control group, n=10)
Sham-operation
(Control group, n=10)
ICMP with
Tezosentan
(n=10)
DOX with
Tezosentan
(n=10)
TAC with
Tezosentan
(n=10)
ICMP without
Tezosentan
(n=10)
DOX without
Tezosentan
(n=10)
TAC without
Tezosentan
(n=10)
Hypertrophic CMP
By TAC
(TAC, n=30)
Doxorubicin-induced
Non-ischemic Dilated
CMP (DOX, n=30)
A
B
Fig. 1. (A) Experimental designs: there are three cardiomy-
opathy rat groups needed and each group was divided into
three sub-groups. As mentioned previously, three groups,
including ischemic dilated cardiomyopathy group (ICMP,
n=30), doxorubicin-induced non-ischemic dilated cardiomy-
opathy group (DOX, n=30) and hypertrophic cardiomyopa-
thy group by Transverse Aortic Constriction method (TAC,
n=30) are prepared. After 1 month following constructions
of cardiomyopathic rat groups, each group was then random-
ly assigned to a SHAM operation (SHAM; control group, n=10) subgroup or tezosentan treatment ischemia-reperfusion subgroup (Tezo,
n=10) or tezosentan non-treatment ischemia-reperfusion subgroup (N-Tezo, n=10). (B) Ischemia-reperfusion injury experimental protocol
(isolated heart perfusion via Langendorff technique): after the stabilization period of 20-30 min, total circulatory arrest for ischemia about
1 hr was performed. After then, reperfusion was performed during 2 hr. In Tezo subgroup, the tezosentan, each 10
-5 M/L concentrations,
is added to the cardioplegic solution and the perfusate. 784 S.M. Ryu, H.J Kim, K.R. Cho, et al.
and perfused retrogradely at a constant pressure of 80 mmHg
with the perfusate (Krebs-Henseleit solution) of the follow-
ing composition: NaCl, 118.1 mM; KCl, 4.6 mM; CaCl2,
2.5 mM; MgSO4, 1.2 mM; KH2PO4, 1.2 mM; NaHCO3,
24.8 mM; and glucose, 10 mM. The perfusate was continu-
ously bubbled with a gas mixture of 95% O2/5% CO2 (pH
7.4), and temperature was maintained at 37℃ throughout
the experiment. A latex balloon filled with water was insert-
ed into the left ventricle through the left atrium and attached
to a pressure transducer (DX-360; Nihon Kohden, Tokyo,
Japan). After 30 min of stabilization period, total circulato-
ry arrest was performed with cardioplegia and coldness about
1 hr. After then, reperfusion was continued for 2 hr. In Tezo
subgroup, tezosentan 10-5 M/L was added to the cardioplegic
solution and the perfusate (Fig. 1B), but not to N-Tezo sub-
group.
Drugs
Tezosentan (Ro 47-0203, Actelion Pharmaceuticals Ltd,
Allschwil, Switzerland) is a non-selective specially formulated
intravenous dual (endothelin-A and -B) endothelin receptor
antagonist. Unlike its sister compound (bosentan), tezosen-
tan is easily soluble in water and stable in solution at physi-
ologic pH, therefore, usable clinically. Another drug, doxoru-
bicin hydrochloride (D1515, Sigma Chemical Co) is well
known for cardioselective toxicity and induces congestive
heart failure.
Hemodynamic studies for cardiac performance
The left ventricular pressure was monitored with a pressure
transducer to obtain the peak positive and negative first de-
rivatives (dP/dTmax and dP/dTmin), and the left ventricular devel-
oped pressure (LVDP) was calculated as the difference bet-
ween the left ventricular (LV) systolic and diastolic pressures.
These parameters were measured by an amplifier (AP601G;
Nihon Kohden) and also recorded using PowerLab/4sp soft-
ware (AD Instruments, Mountain View, CA, U.S.A.). Coro-
nary flow was also determined by collecting the coronary
effluent from the hearts.
Statistical analysis
All data are presented as means±standard error of the mean.
The comparisons among three groups were carried out by
Kruskal-Wallis Test. Differences were considered significant
at P<0.05. 
RESULTS
Left ventricular developed pressure (LVDP)
LVDP of Tezo subgroup was significantly higher than that
of N-Tezo subgroup in the ICMP group after 30 min of reper-
fusion (64.3±7.1 mmHg vs. 41.4±4.3 mmHg; P<0.05).
In the DOX or TAC model, LVDPs were not significantly
different between Tezo and N-Tezo subgroup during the entire
reperfusion period (Fig. 2A, Table 1).
dP/dT
max
In the ICMP group, dP/dTmax was significantly different
among the three subgroups at 30 min of reperfusion (SHAM,
3,491±21 mmHg/sec; Tezo, 2,821±13 mmHg/sec; N-
Tezo, 2,282±182 mmHg/sec; P<0.05). In the DOX or TAC
groups, there were no statistical differences among three sub-
groups (Fig. 2B, Table 1).
dP/dT
min
In the ICMP group, dP/dT
min was significantly different
among the three subgroups at 30 min of reperfusion (SHAM,
-2,382±114 mmHg/sec; Tezo, -1,638±130 mm Hg/sec;
N-Tezo, -1,387±81; P<0.05), similar to the above dP/dTmax.
In the DOX or TAC groups, there were no statistically sig-
nificant differences among the three subgroups (Fig. 2C,
Table 1).
Coronary blood flow (CBF)
Only in the ICMP group, there were significant differences
*Hemodynamic variables are significantly different among SHAM, Tezo and N-Tezo subgroups at 30 min of reperfusion (P<0.05).
ICMP, ischemic cardiomyopathy rat group; DOX, doxorubicin treated non-ischemic dilated cardiomyopathy rat group; TAC, hypertrophic cardiomyopathy
rat group by transverse aortic constriction; SHAM, Sham operated ischemia-reperfusion subgroup; Tezo, tezosentan treated ischemia-reperfusion
subgroup; N-Tezo, tezosentan non-treatment ischemia-reperfusion subgroup; LVDP, left ventricular developed pressure; CBF, coronary blood flow.
ICMP*
SHAM Tezo N-Tezo
DOX
SHAM Tezo N-Tezo
TAC
SHAM Tezo N-Tezo
LVDP (mmHg) 75.2±5.3 64.3±7.1 41.4±4.3 46.8±3.2 45.1±2.9 45.6±3.8 75.2±4.2 56.2±3.2 58.7±2.9
dP/dT
max (mmHg/sec) 3,491±21 2,821±13 2,282±182 2,095±11 2,320±13 2,559±18 3,491±9 2,100±11 1915±7
dP/dT
min (mmHg/sec) -2,382±114 -1,638±130 -1,387±81 -1,639±184 -1,745±97 -2,085±81 -2,382±97 -1,532±93 -1,432±76
CBF (mL/min) 33.9±4.0 26.3±3.3 19.1±2.1 32.1±2.4 24.2±2.3 20.1±1.9 33.4±2.1 24.5±4.2 22.4±3.6
Table 1. Variable hemodynamic parameters at the reperfusion 30 minMyocardial Protective Effect of Tezosentan 785
Control Teso N-Teso
Fig. 2. The results of cardiac performance. (A) LV developed pressure (LVDP) during ischemia-reperfusion injury. (B) dP/dT
max during ische-
mia-reperfusion injury. (C) dP/dT
min during ischemia-reperfusion injury. (D) Coronary blood flow (CBF) during ischemia-reperfusion injury.
*P<0.05 at 30 min of reperfusion among SHAM, Tezo and N-Tezo subgroups.
NS, there is no statistical significance among subgroups; ICMP, ischemic cardiomyopathy rat group; DOX, doxorubicin treated non-ischemic
dilated cardiomyopathy rat group; TAC, hypertrophic cardiomyopathy rat group by transverse aortic constriction; SHAM, Sham operated
ischemia-reperfusion subgroup; Tezo, tezosentan treated ischemia-reperfusion subgroup; N-Tezo, tezosentan non-treatment ischemia-
reperfusion subgroup.
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among three subgroups after 30 min of reperfusion in the CBF
(SHAM; 33.9±4.0 mL/min vs. Tezo; 26.3±3.3 mL/min
vs. N-Tezo; 19.1±1.1 mL/min; P<0.05) (Fig. 2D, Table 1).
DISCUSSION
The effect of endothelin-1, the principal isoform of endothe-
lin, is mediated by 2 types of receptor, endothelin-A and en-
dothelin-B. The endothelin-A receptor appears to mediate
vasoconstriction and stimulate the secretion of atrial natriuret-
ic peptide, while the endothelin-B receptor mediates endo-
thelin-induced vasodilatation and activation of the renin-an-
giotensin-aldosterone system. Through these effects, endo-
thelin has been demonstrated to be not only one of the most
potent vasoconstrictors known, but also to mediate patho-
logic hypertrophy and fibrosis of both ventricular and vas-
cular tissues, thus promoting progression of atherosclerosis,
ventricular and vascular remodeling (6-8).
Tezosentan, a dual inhibitor of endothelin A and B recep-
tors, is weakly acidic, highly soluble in water and stable in
physiologic pH solution. These properties make it an ideal
candidate for intravenous use, and are the reason of why we
used tezosentan in our study. 
Heart failure has been associated with elevated plasma lev-
els of endothelin-1, and the magnitude of the elevation with
the severity of disease, the incidence of arrhythmia, and a worse
prognosis. Increased endothelin levels have been described
in patients with acute and chronic CHF that are predictive
of increased mortality risk (9). Furthermore, increased endothe-
lin levels have been suggested to play an important role in
the increased systemic vascular resistance seen in CHF (10).
Therefore, endothelin seems to play a major role in the patho-
genesis of experimental and clinical heart failure (11, 12).
Although the endothelin receptor antagonists may have
the ability to improve the outcome of heart failure by reduc-
ing preload and afterload, increasing the contractility of fail-
ing myocardium, delaying myocyte hypertrophy, and reduc-
ing the incidence of arrhythmias, some studies demonstrat-
ed no benefit of the endothelin receptor antagonists for myo-
cardial ischemia-reperfusion heart models (13-15). Therefore,
we aimed to investigate the myocardial protective effects of
tezosentan for the ischemia-reperfusion injury in various heart
failure models.
Before analyzing our experimental data, it was necessary
to confirm the in-depth of animal heart failure models. There-
fore, one month after cardiomyopathic animal models had
been constructed, they were verified with pathologic speci-
mens during euthanasia of the experimental animals. In the
ICMP models, staining of triphenyltetrazolium chloride with
evans blue was used for visualizing ischemia-infarct area of
myocardium. In the DOX models, dilated myocardium was
confirmed with pathologic specimens and hypertrophied myo-
cardium was also confirmed in the TAC models (Fig. 3).
We also believe that hemodynamic parameters such as
LVDP, dP/dTmax, dP/dTmin and CBF are adequate in our pre-
sent study to verify myocardial protective effect of tezosen-
tan in various rat cardiomyopathy models. It should be men-
tioned that these parameters have been used for proving drug
efficacy in Langendorff technique (16).
As a result, our present study did not reveal any significant
effect of tezosentan on DOX and TAC models. There are some
hypotheses and limitations on this result in our study. First,
although heart failure has been associated with elevated plas-
ma levels of endothelin-1, the density of endothelin and en-
dothelin binding sites had been produced in the heart has not
been uniform among different animal heart failure models
(17). In myocardial infarct model, it is well established that
the infarcted myocardium induces the myocardial necrosis,
and increases endothelin-1 levels many fold not only in the
post-acute myocardial infarct scar tissues but also in the healed
infarct scars after 4 and 13 weeks (18-20). Therefore, endothe-
Fig. 3. (A) In the ICMP models, staining of triphenyltetrazolium chloride with evans blue was used for visualizing ischemia-infarct area of
myocardium (black dash). (B) In the DOX models, dilated myocardium was confirmed with pathologic specimens (white arrow-enlarged
left ventricle). (C) In the TAC models, hypertrophied myocardium was confirmed with pathologic specimens (white arrow).
*The scale of the ruler in the photo is millimeter (mm).
ICMP, ischemic cardiomyopathy rat group; DOX, doxorubicin treated non-ischemic dilated cardiomyopathy rat group; TAC, hypertrophic
cardiomyopathy rat group by transverse aortic constriction.
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lin-1, a recognized fibrogenic factor, plays a crucial role in
the stabilization of the necrotic area and in the healing of the
scar (20). However, the most prominent histological feature
of DOX is not the myocyte necrosis, but the loss of myofib-
rils and cytoplasmic vacuolization caused by dilatation of the
sarcoplasmic reticulum in the myocardial cells (21), and there
is a report that high dose of endothelin antagonist is needed
to block endothelin induced hypertension in the dilated car-
diomyopathy rat models (22). In addition, sustained pressure
overload stimulate pathological cardiac hypertrophy and dys-
function (23) and hypertrophy progresses to decompensated
phase with cardiac dilatation and contractile impairment dur-
ing chronic pressure overload (24, 25). Some authors showed
that the production of endothelin-1 increased in the hyper-
trophied left ventricle (26), but it depends on the time of the
disease progress. Ventricular endothelin-1 levels and the den-
sity of endothelin-1 binding sites were increased significant-
ly, without affecting their binding affinity, on day 8 of pres-
sure overload (27), after then, the production of endothelin-
1 is decreased and endothelin receptors are down-regulated
in hypertrophied ventricles 8 weeks after aortic coarctation
(28). However, it is also reported that endothelin-1 levels in
subjects with heart failure in whom they are found to be ele-
vated in the late, decompensated phase of the disease (29).
This time-dependant up- and down-regulations of endothe-
lin and endothelin receptors are also another proof for our
hypothesis. That is, because of the differences of pathophys-
iology among our study group, cardiac endothelin-1 and en-
dothelin receptors might not uniformly be induced in vari-
ous heart failure models.
Second, in addition to endothelin, renin-angiotensin-aldos-
terone, epinephrine-norepinephrine, and natriuretic peptide
have also been identified as neurohormones to be activated
in cardiomyopathy (30). It is well known that doxorubicin
administration has been shown to activate the renin-angio-
tensin system (31, 32) and the atrial natriuretic peptide level
has also been increased relative to the severity of the cardiac
dysfunction in human (32). And, there is a study on angio-
tensin and angiotensin receptor antagonist in the hypertro-
phic cardiomyopathy (33), showing that stimulation of the
angiotensin receptor has an important role in disease process
during pressure overload. Therefore, these neurohormones
might be more important disease mediators in the DOX or
TAC models than in the ICMP model.
There was a limitation to our study. Endothelin is a stim-
ulator of polymorphonuclear leukocyte (PMN) aggregation
(34) and adhesion as well as a potent vasoconstrictor. Myocar-
dial ischemia initiates an acute inflammatory response in
which PMNs are of importance (35). Because we had used
isolated heart perfusion using Langendorff technique, how-
ever, most of the PMNs were diluted in the buffer perfused
isolated heart. In other words, the effect of PMNs might be
restricted and it can affect the results in our study. 
In conclusion, our result reveals that tezosentan has myocar-
dial protective effects for the ischemia-reperfusion injury in
the ischemic cardiomyopathy model, but not in the doxoru-
bicin-induced cardiomyopathy and pressure-overload hyper-
trophic heart failure models. 
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